Quoin pharmaceuticals files u.s. and international patent applications for novel topical rapamycin formulations to treat rare disease indications

Ashburn, va., march 04, 2025 (globe newswire) -- quoin pharmaceuticals ltd. (nasdaq: qnrx) (the “company” or “quoin”), a late clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced it has filed u.s. and international patent applications for novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare diseases including microcystic lymphatic malformations, venous malformations and angiofibromas. the products are being developed using quoin's in-licensed proprietary invisicare delivery technology. there are currently no fda approved treatments for either microcystic lymphatic malformations or venous malformations.
QNRX Ratings Summary
QNRX Quant Ranking